Literature DB >> 20479012

Effect of smoking on the serum levels of 25-hydroxyvitamin D depends on the assay employed.

Guri Grimnes1, Bjørg Almaas, Anne Elise Eggen, Nina Emaus, Yngve Figenschau, Laila Arnesdatter Hopstock, Moira Strand Hutchinson, Paal Methlie, Albena Mihailova, Monica Sneve, Peter Torjesen, Tom Wilsgaard, Rolf Jorde.   

Abstract

OBJECTIVE: Because we found higher serum 25-hydroxyvitamin D (25(OH)D) levels among smokers than among non-smokers with analyses using an electrochemiluminescence immunoassay (ECLIA) from Roche, the purpose of the present study was to examine whether this difference between smokers and non-smokers was maintained using other serum 25(OH)D assays.
DESIGN: A cross-sectional population-based study on 6932 participants from the Tromsø study, 1994-1995, and one validation study comparing six different serum 25(OH)D assays in 53 non-smokers and 54 smokers were performed.
METHODS: The association between smoking, season and serum 25(OH)D as measured by ECLIA (Roche) was assessed in the population-based study using general linear models with multivariate adjustments. In the validation study, serum levels of 25(OH)D were analysed with liquid chromatography coupled with mass spectrometry assay from two different laboratories, RIA (DiaSorin), HPLC, RIA (IDS) and ECLIA (Roche). T-tests and linear mixed model analyses were performed to compare the serum 25(OH)D levels in smokers and non-smokers within and between the methods.
RESULTS: In the population-based study, the serum levels of 25(OH)D using the ECLIA method were 51.9, 53.2 and 72.0 nmol/l in never, former and current smokers (P<0.01). In the validation study, the serum concentration of 25(OH)D was 10.3 nmol/l higher in smokers than in non-smokers (P<0.01) using the ECLIA (Roche), while non-significantly lower serum levels of 25(OH)D were found in smokers using the other five methods.
CONCLUSIONS: These two studies indicate that the ECLIA (Roche) overestimates serum 25(OH)D levels in smokers by unknown mechanisms. If confirmed, this might have clinical consequences, and the issue needs further exploration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479012     DOI: 10.1530/EJE-10-0150

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  33 in total

1.  Tracking of serum 25-hydroxyvitamin D during 21 years.

Authors:  Julia Kubiak; Elena Kamycheva; Rolf Jorde
Journal:  Eur J Clin Nutr       Date:  2020-12-11       Impact factor: 4.016

2.  Pre-diagnostic vitamin D concentrations and cancer risks in older individuals: an analysis of cohorts participating in the CHANCES consortium.

Authors:  José Manuel Ordóñez-Mena; Ben Schöttker; Veronika Fedirko; Mazda Jenab; Anja Olsen; Jytte Halkjær; Ellen Kampman; Lisette de Groot; Eugene Jansen; H Bas Bueno-de-Mesquita; Petra H Peeters; Galatios Siganos; Tom Wilsgaard; Laura Perna; Bernd Holleczek; Ulrika Pettersson-Kymmer; Philippos Orfanos; Antonia Trichopoulou; Paolo Boffetta; Hermann Brenner
Journal:  Eur J Epidemiol       Date:  2015-05-15       Impact factor: 8.082

Review 3.  Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies.

Authors:  Lu Wang; Yiqing Song; Joann E Manson; Stefan Pilz; Winfried März; Karl Michaëlsson; Annamari Lundqvist; Simerjot K Jassal; Elizabeth Barrett-Connor; Cuilin Zhang; Charles B Eaton; Heidi T May; Jeffrey L Anderson; Howard D Sesso
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-11-13

4.  Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.

Authors:  Egil Røsjø; Linn H Steffensen; Lone Jørgensen; Jonas C Lindstrøm; Jūratė Šaltytė Benth; Annika E Michelsen; Pål Aukrust; Thor Ueland; Margitta T Kampman; Øivind Torkildsen; Trygve Holmøy
Journal:  J Neurol       Date:  2015-10-01       Impact factor: 4.849

5.  The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial.

Authors:  G Grimnes; R Joakimsen; Y Figenschau; P A Torjesen; B Almås; R Jorde
Journal:  Osteoporos Int       Date:  2011-09-10       Impact factor: 4.507

6.  Association of Smoking with the Blood Concentration of 25-Hydroxy Vitamin D and Testosterone at High and Low Altitudes.

Authors:  Gaffar Sarwar Zaman; Safar Abadi Saeed Al-Saleem Alshahrani; Nasrin Banu Laskar; Ibrahim Hadadi; Magbool Alelyani; Mohamed Adam; Mohammed Babiker; Mustafa Jafar Musa; Pranab Barua; Mohammed Elimam Ahamed Mohammed
Journal:  Int J Gen Med       Date:  2022-02-07

7.  What is needed to keep persons with multiple sclerosis vitamin D-sufficient throughout the year?

Authors:  Linn H Steffensen; Magritt Brustad; Margitta T Kampman
Journal:  J Neurol       Date:  2012-08-01       Impact factor: 4.849

8.  Does rosuvastatin increase serum levels of 25-hydroxy-vitamin D?

Authors:  Hartmut H Glossmann; Mario Blumthaler
Journal:  Dermatoendocrinol       Date:  2012-01-01

9.  Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromsø Study.

Authors:  Rolf Jorde; Henrik Schirmer; Tom Wilsgaard; Ragnar Martin Joakimsen; Ellisiv Bøgeberg Mathiesen; Inger Njølstad; Maja-Lisa Løchen; Yngve Figenschau; Jens Petter Berg; Johan Svartberg; Guri Grimnes
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

10.  Serum vitamin D in patients with chronic obstructive lung disease does not correlate with mortality--results from a 10-year prospective cohort study.

Authors:  Dennis Back Holmgaard; Lone Hagens Mygind; Ingrid Louise Titlestad; Hanne Madsen; Palle Bach Nielsen Fruekilde; Svend Stenvang Pedersen; C Pedersen
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.